Table 1.
Summary of Clinicopathologic Characteristics of Benign and Malignant Melanocytic Samples
| Characteristic | Patient Group |
Exploratory P‡ | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Primary Melanoma (newly developed)*† |
Nevi Removed During BRAF Inhibition Therapy*† |
Common Nevi*† |
||||||||
| No. | Median | Range | No. | Median | Range | No. | Median | Range | ||
| Total No. of patients | 11 | 8 | 21 | — | ||||||
| Female | 4 | 1 | 12 | .16 | ||||||
| Age at diagnosis, years | 51 | 22–77 | 48 | 44–66 | 45 | 20–76 | .35 | |||
| No. of weeks receiving selective BRAF inhibition therapy | 8 | 4–27 | 17.5 | 2–42 | — | — | ||||
| No. of suspected chronic sunlight-exposed tumor localizations§ | 5 | 2 | 5 | — | ||||||
| BRAF V600E | 0 | 0 | 8 | — | ||||||
| NRAS Q61K/Q61R | 1 | 2 | 0 | — | ||||||
| pERK | ||||||||||
| SI | 2 | 1–3 | 2 | 1–2 | 2 | 1–3 | .15 | |||
| NP | 3 | 2–3 | 2 | 1–3 | 2.5 | 1–3 | .19 | |||
| Score¶ | 5 | 4–6 | 4 | 3–5 | 4 | 3–6 | .07 | |||
| pAKT | ||||||||||
| SI | 3 | 2–3 | 2 | 2–3 | 2 | 1–3 | .16 | |||
| NP | 3 | 3–3 | 3 | 2–3 | 3 | 2–3 | .19 | |||
| Score¶ | 6 | 5–6 | 5 | 4–6 | 5 | 3–6 | .03∥ | |||
| IGF-1Rβ | ||||||||||
| SI | 3 | 2–3 | 2 | 2–3 | 2 | 2–3 | .13 | |||
| NP | 3 | 2–3 | 3 | 3–3 | 3 | 2–3 | .43 | |||
| Score¶ | 6 | 4–6 | 5 | 5–6 | 5 | 4–6 | .23 | |||
| Cyclin D1 | ||||||||||
| NP in the epidermis | 3 | 0–3 | 3 | 1–3 | 2 | 0–3 | .20 | |||
| NP in the dermis | 2 | 1–3 | 2 | 1–3 | 1 | 0–2 | .01∥ | |||
Abbreviations: IGF-1Rβ, insulin-like growth factor 1 receptor beta; NP, number of positive cells; pAKT, phospho-AKT; pERK, phospho-ERK; SI, staining intensity.
Results for only the first tumor considered (four patients with two lesions); results were similar (and claims identical) if the second tumor was considered.
Note that information on some characteristics was missing; the summary pertains to the available information only.
Two-sided from either generalized Fisher's exact test for 2 × 3 tables or the exact Kruskal-Wallis test; not calculated when group comparison was either not possible or when variation was too limited.
Summarizes face, forearm, hand, neck, right arm, upper arm, scalp, temple, cheek.
Score, sum of SI and NP.
Exploratory testing of the combined patients with primary melanoma (newly developed) and patients with nevi removed during BRAF inhibition compared with patients with common nevi by two-sided exact Wilcoxon and Mann-Whitney U tests resulted in 0.04 for the pAKT score and 0.01 for cyclin D NP in the dermis.